Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 18/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3562320 | 0.88 | CHEK2 (0.85) | CHEK2 | |
| SCHEMBL5178035 | 0.87 | CHEK2 (0.67) | CHEK2MEN1KMT2AKDM4EPOLB | |
| SCHEMBL5178365 | 0.85 | CHEK2 (0.67) | CHEK2MEN1KMT2AKDM4EPOLB | |
| SCHEMBL3568831 | 0.85 | CHEK2 (0.71) | CHEK2MEN1KMT2AKDM4EPOLB | |
| SCHEMBL5177231 | 0.84 | CHEK2 (0.67) | CHEK2MEN1KMT2AMAPTRAB9A | |
| SCHEMBL5177946 | 0.83 | CHEK2 (0.66) | CHEK2MEN1KMT2ATHRB | |
| SCHEMBL5177595 | 0.82 | CHEK2 (0.68) | CHEK2 | |
| SCHEMBL5178404 | 0.81 | CHEK2 (0.63) | CHEK2MEN1KMT2ATHRB | |
| SCHEMBL5178851 | 0.81 | CHEK2 (0.67) | CHEK2MEN1KMT2AKDM4EPOLB | |
| SCHEMBL5253625 | 0.81 | CHEK2 (0.69) | CHEK2MEN1KMT2AKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1613313-B1 | 2-PHENYL-BENZIMIDAZOL AND 2-PHENYL-IMIDAZO-4,5]-PYRIDINE DERIVATIVES AS CHECKPOINT KINASE CDS1 (CHK2) INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2007-06-06 | — | — | EP | claimed |